Antiepileptic drugs and the regulation of mood and quality of life (QOL): The evidence from epilepsy

Epilepsia

Volumn 46, Issue SUPPL. 4, 2005, Pages 50-57

  Selai, Caroline ^a   Bannister, Debbie ^a   Trimble, Michael ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AEDs; Carbamazepine; Health status; Lamotrigine; Outcome; Quality of life

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAERGIC RECEPTOR AFFECTING AGENT; GABAPENTIN; LAMOTRIGINE; MOOD STABILIZER; TIAGABINE; TOPIRAMATE; VIGABATRIN; TRIAZINE DERIVATIVE;

AMYGDALOID NUCLEUS; ANTICONVULSANT THERAPY; DRUG EFFECT; DYSPHORIA; EPILEPSY; HUMAN; IRRITABILITY; MOOD DISORDER; NERVE CELL NETWORK; NEUROANATOMY; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; AFFECT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEALTH STATUS; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL;

AFFECT; ANTICONVULSANTS; CARBAMAZEPINE; EPILEPSY; HEALTH STATUS; HUMANS; MOOD DISORDERS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TRIAZINES;

EID: 20544477585     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.463010.x     Document Type: Review

References (42)

1. Robertson MM. Affect and mood in epilepsy: an overview with a focus on depression. Acta Neurol Scand 1992;140:127-32.
2. Blumer D. Dysphoric disorders and paroxysmal affects: recognition and treatment of epilepsy related psychiatric disorders. Harv Rev Psychiatry 2000;8:8-17.
3. Dalby M. Behavioural effects of carbamazepine. In: Penry JK, Daly DD, eds. Advances in neurology, 11th ed. New York: Raven Press. 1975:331-44.
4. Trimble MR, Corbett JA. Behavioural and cognitive disturbances in epileptic children. Irish Med J 1980;73(suppl 1):21-8.
5. Robertson MM, Trimble MR, et al. Phenomenology of depression in epilepsy. Epilepsia 1987;284:364-72.
6. Rodin E, Schmaltz S. The Bear-Fedio inventory and temporal lobe epilepsy. Neurology 1984;34:591-6.
7. Andrewes DG, Bullen JG, Tomlinson L, et al. A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. Epilepsia 1986;27:128-34.
8. Kanner AM, Palac S. Depression and epilepsy, a common but often unrecognised comorbid malady. Epilepsy Behav 2000;1:37-51.
9. Schmitz B. The effects of anti-epileptic drugs on behaviour. In: Trimble M, Schmitz B, eds. The neuropsychiatry of epilepsy. Cambridge: Cambridge University Press, 2002:241-55.
10. Smith D, Baker G, Davies G, et al. Outcomes of add on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-22.
11. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. Oxford: Oxford University Press, 1987.
12. Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new health-related quality of life instrument. In: Spilker B, ed. Quality of life and pharmacoeconomic in clinical trials. Philadelphia: Lippincott-Raven, 1996:49-56.
13. Trimble MR, Dodson WE. Epilepsy and quality of life. New York: Raven Press, 1994.
14. Cramer J. Quality of life and compliance. In: Trimble MR, Dodson WE, eds. Epilepsy and quality of life. New York: Raven Press, 1994.
15. Stalgis C. The impact of quality of life for the development and marketing of antiepileptic drugs. In: Trimble MR, Dodson WE, eds. Epilepsy and quality of life. New York: Raven Press, 1994:175-82.
16. Trimble MR. Quality of life and cognitive function. In: Trimble MR. Dodson WE, eds. Epilepsy and quality of life. New York: Raven Press, 1994:183-98.
17. Aldenkamp A-P, Arends J, Bootsma H-P, et al. Randomized doubleblind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002;431:19-26.
18. Martin R, Kuzniecky R, Hetherington H, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52:321-7.
19. Placidi F, Marciani M-G, Diomedi MP, et al. Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy. Acta Neurol Scand 2000;1022:81-6.
20. Meador KJ, Loring DW, Wray MPG, et al. Differential cognitive and behavioural effects of carbamazepine and lamotrigine. Neurology 2001;56:1177-82.
21. Bialer M, Johannessen S-I, Kupferberg H-J, et al. Progress report on new antiepileptic drugs: summary of the fourth Eilat conference, EILAT IV. Epilepsy Res 1999;341:1-41.
22. Aldenkamp AP, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2001;2:85-91.
23. Ramaratnam S, Marson AG, Baker GA. Lamotrigine: add-on for drug-resistant partial epilepsy: Cochrane review. In: Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons, 2004.
24. Buchanan N. The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Seizure 1995;4:233-6.
25. Buchanan N. Lamotrigine: clinical experience in 93 patients with epilepsy. Acta Neurol Scand 1995;92:28-32.
26. Kaminow L, Schimschock JR, Hammer AE, et al. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy Behav 2003;46:659-66.
27. Selai CE, Trimble MR. Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value? Seizure 1998;7:417-8.
28. Selai CE; Smith K; Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure 1999;8:8-13.
29. Kaiser S, Selai C-E, Trimble MR. Long-term follow-up of topiramate and lamotrigine: a perspective on quality of life. Seizure 2002;116:356-60.
30. Chimielewska B, Stelmasiak Z. Clinical evaluation of Gabitril and Lamictal for drug-resistant epilepsy in adults. Ann Univ Marine Curie Skoldowska Med 2001;56:35-42.
31. Gillham R, Baker G, Thompson P, et al. Standardisation of a self-report questionnaire for use in evaluation cognitive, affective and behavioural side effects of antiepileptic drug treatments. Epilepsy Res 1996;241:47-55.
32. Gillham R, Kane K, Bryant-Comstock L, et al. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000;96:375-9.
33. Steiner T-J, Dellaportas CI, Findley L-J, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;405:601-7.
34. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;342:312-22.
35. Smith D, Chadwick D, Baker G, et al. Seizure severity and the quality of life. Epilepsia 1993;34(suppl 5):S31-5.
36. Cramer JA, Hammer AE, Kustra RP. Quality of life improvement with conversion to lamotrigine monotherapy. Epilepsy Behav 2004;5:224-30.
37. Sackellares JC, Kwong WJ, Vuong A, et al. Lamotrigine monotherapy improves health-related quality of life in epilepsy: a doubleblind comparison with valproate. Epilepsy Behav 2002;3:372-86.
38. Mula M, Trimble MR, Thompson P, et al. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 2003;607:1104-7.
39. Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003;615:704-6.
40. Otsuki K, Morimoto K, et al. The effects of lamotrigine and conventional antiepileptic drugs on amygdala and hippocampal-kindled seizures in rats. Epilepsy Res 1998;312:101-12.
41. Stratton C, Large CH, Cox B, et al. Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindled model. Epilepsy Res 2003;53:95-106.
42. Tebartz van Elst L, Woermann F, Lemieux L, et al. Amygdala enlargement in dysthymia: a volumetric study in people with temporal lobe epilepsy. Biol Psychiatry 1999;46:1614-23.